Intervention Review

Angiogenesis inhibitors for the treatment of ovarian cancer

  1. Kezia Gaitskell2,
  2. Igor Martinek3,
  3. Andrew Bryant4,
  4. Sean Kehoe3,
  5. Shibani Nicum5,
  6. Jo Morrison1,*

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 7 SEP 2011

Assessed as up-to-date: 20 JUL 2011

DOI: 10.1002/14651858.CD007930.pub2

How to Cite

Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD007930. DOI: 10.1002/14651858.CD007930.pub2.

Author Information

  1. 1

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

  2. 2

    London School of Hygiene & Tropical Medicine, London, UK

  3. 3

    Oxford Cancer and Haematology Centre, Oxford Gynaecological Oncology Centre, Level 0, Oxford, UK

  4. 4

    Newcastle University, Institute of Health and Society, Newcastle upon Tyne, UK

  5. 5

    Oxford Cancer and Haematology Centre, NHS Department of Oncology, Level 2, Oxford, UK

*Jo Morrison, Department of Obstetrics and Gynaecology, Musgrove Park Hospital, Taunton, Somerset, TA1 5DA, UK. jo.morrison@obs-gyn.ox.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 7 SEP 2011

SEARCH

  1. Current Version

    Angiogenesis inhibitors for the treatment of ovarian cancer

    Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum and Jo Morrison

    Article first published online: 7 SEP 2011 | DOI: 10.1002/14651858.CD007930.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Angiogenesis-inhibitors for the treatment of ovarian cancer

    Kezia Gaitskell, Igor Martinek, Shibani Nicum, Sean Kehoe and Jo Morrison

    Article first published online: 8 JUL 2009 | DOI: 10.1002/14651858.CD007930